Organon Strikes $100m+ Global Deal For Henlius’ Denosumab And Pertuzumab

Gains Rights To Perjeta And Prolia/Xgeva Biosimilars As Well As Ipilimumab Option

 
• By David Wallace
  
Deal handshake with US and China flags
US-based Organon has struck a deal with China’s Henlius • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Deals

More from Business